FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 3, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $144.7 million. Free cash flow was -$123.5 million. As of Sep 30, 2026 it held $768.1 million in cash and investments and $4.9 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-144.74M
+52.0% vs prior year
Operating cash flow (TTM)
$-129.88M
+15.9% vs year-ago TTM
Free cash flow (TTM)
$-130.02M
+15.9% vs year-ago TTM
EPS
$-1.53
+65.5% vs prior year
Dividend per share
None
Shares outstanding
110.54M
+24.8% vs prior year
Net cash
$763.19M
as of Sep 30, 2026
Operating margin
-360.2%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1658551
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M |
| Net income | -$144.7M | -$301.7M | $49.3M | -$198.4M |
| Diluted EPS | -$1.53 | -$4.43 | $0.70 | -$3.39 |
| Operating cash flow | -$123.3M | -$167.6M | $11.9M | -$179.9M |
| Free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M |
| Stockholders' equity | $305.3M | $164.8M | $433.4M | $340.6M |
| Cash and investments | $317.0M | $176.5M | $371.4M | $346.9M |
| Total debt | $6.0M | $2.0M | $4.2M | $6.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 20, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 18, 2026 |
All 440 Amylyx Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.